Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

September 5, 2023

Study Completion Date

September 5, 2023

Conditions
Hematological Malignancies
Interventions
DRUG

Magrolimab

Administered intravenously

DRUG

Azacitidine

Administered according to region-specific drug labeling either subcutaneously or intravenously

Trial Locations (27)

10021

Weill Cornell Medical College - New York-Presbyterian Hospital, New York

10029

Icahn School of Medicine at Mount Sinai, New York

10032

Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center, New York

10467

Montefiore Medical Center, The Bronx

14263

Roswell Park Cancer Institute, Buffalo

27599

University of North Carolina at Chapel Hill, Chapel Hill

27705

Duke University Medical Center, Durham

33136

University Of Miami - Miller School Of Medicine, Sylvester Comprehensive Cancer Center, Miami

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

37203

Tennesssee Oncology - Centennial Clinic Location, Nashville

43210

Ohio State University Medical Center, Columbus

53226

Medical College of WI Froedtert Hospital, Milwaukee

60637

The University of Chicago, Chicago

64132

Mid America Division, Inc., Kansas City

73104

Stephenson Cancer Center, Oklahoma City

75246

Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center, Aurora

90095

UCLA Clinical and Translational Research Center (CTRC), Los Angeles

91010

City of Hope National Medical Center, Duarte

92093

University of California San Diego (UCSD), La Jolla

92868

Chao Family Comprehensive Cancer Center - UC Irvine Medical Center, Orange

94305

Stanford University Medical Center, Stanford

95817

University of California Davis Comprehensive Cancer Center, Sacramento

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute/ Boston Children's Hospital, Boston

OX3 7LE

Oxford Centre for Respiratory Medicine Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT03248479 - Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies | Biotech Hunter | Biotech Hunter